Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the α7 nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats

BACKGROUND: Alpha 7 nicotinic acetylcholine receptor (α7nAChR) agonists have been developed to treat schizophrenia but failed in clinical trials due to rapid desensitization. GAT107, a type 2 allosteric agonist-positive allosteric modulator (ago-PAM) to the α7 nAChR was designed to activate the α7 n...

Descripción completa

Detalles Bibliográficos
Autores principales: Brems, Brittany M., Sullivan, Erin E., Connolly, Jenna G., Zhang, Jingchun, Chang, Arnold, Ortiz, Richard, Cantwell, Lucas, Kulkarni, Praveen, Thakur, Ganesh A., Ferris, Craig F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326388/
https://www.ncbi.nlm.nih.gov/pubmed/37424993
http://dx.doi.org/10.3389/fnins.2023.1196786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326388/
https://www.ncbi.nlm.nih.gov/pubmed/37424993
http://dx.doi.org/10.3389/fnins.2023.1196786

Ejemplares similares